Cross-Sector entity
FDA is the most frequent co-covered peer, appearing in 5 of the 20 tracked stories. Across a 170-day span, the pace is roughly 0.8 stories per week. The busiest single day carried 4. Coverage clusters in pharma, which accounts for 5 of those 20, with the remainder spread across 4 other categories.
31 verified stories tracked
Last mentioned: 5d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 45 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FDA is the most frequent co-covered peer, appearing in 5 of the 20 tracked stories. Across a 170-day span, the pace is roughly 0.8 stories per week. The busiest single day carried 4. Coverage clusters in pharma, which accounts for 5 of those 20, with the remainder spread across 4 other categories. Moderna appears in 20 tracked Cross-Sector stories published from March 4, 2026 through August 20, 2026. Negative sentiment appears in 0% of the tracked stories. Each carries 3.1 original sources on average.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Moderna. Shared-story counts are live from our verified record — not editorial picks.
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
FDA final decision deadline
The agency must decide whether to approve the first mRNA-based influenza vaccine, with major implications for the platform’s future.
FDA Approval of mRNA-1010
The FDA approved Moderna's mRNA flu vaccine for adults 50+, with traditional approval for ages 50–64 and accelerated approval for ages 65+.
Advisory panel recommends approval
The FDA’s Vaccines and Related Biological Products Advisory Committee votes to recommend the mRNA flu shot for licensure.
Court Ruling
Judge Brian Murphy issues a stay, halting the implementation of the vaccine overhaul.
Settlement Reached
Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.
Legal Challenge
The AAP and ACP file suit in Massachusetts federal court to block the changes.
Thursday Pre-Market
Key reports from Moderna, Newmont, Keurig Dr Pepper, Cheniere Energy, and Viatris.
FDA U-Turn
FDA agrees to review the application after resolving the public dispute.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Public Dispute
Moderna and administration officials engage in a public disagreement over the regulatory path forward.
Public Dispute
Reports emerge that career FDA scientists were overruled, leading to a public standoff between Moderna and the agency.
Political Controversy
Reports emerge that the vaccine chief overruled career scientists to block the shot.
Initial Rejection
Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.
Initial Rejection
Trump administration vaccine chief refuses to review Moderna's mRNA flu shot application.
FDA refuses to review Moderna’s mRNA flu vaccine
FDA sends a refusal-to-file letter, stunning Moderna executives. Moderna had prior indications that a review would proceed.
FDA reverses decision after industry backlash
About a week later, FDA agrees to review the application after Moderna commits to a confirmatory post-market study, following public outcry and pressure.
FDA Issues Refuse-to-File Letter
FDA informs Moderna it will not review the mRNA flu shot application, surprising the company after prior assurances.
FDA Accepts Application After Outcry
A little over a week later, the agency reverses its decision after Moderna commits to a confirmatory study.
For finance readers, Aug. 19 was a case study in cross-asset relief: Treasury buyback news pulled the 30-year yield off its highest since 2007, feeding a 0.21% S&P 500 gain, while a more than 137% Moderna surge drove healthcare to a record 2.9% gain. The support for risk appetite masks a hawkish Fed minutes message and an unresolved long-term rate threat to AI-heavy valuations.
Moderna's mRNA cancer therapy readout sent its shares up as much as 177%, driving a 2.9% record gain in the S&P 500 healthcare sector amid easing Treasury yields. The rally lifted peers including Merck, BioNTech and Novavax, but macro rate worries persist.
Source: Sph Media (sg) · Reuters (my)
MarketBeat's August 19 high-volume value screen names Moderna, QQQ, Intel, Nebius, and SpaceX, while a large-cap screen adds SanDisk and Micron. The list highlights where dollar volume concentrated, but classifications include an ETF and a private company, so investors should validate the data before acting.
Moderna appears on both MarketBeat's value and large-cap high-volume screens on August 19, underscoring unusual liquidity and renewed biotech interest despite a post-COVID valuation reset. The mRNA pipeline spans respiratory, latent, and public health vaccines, setting up multiple clinical catalysts.
Source: watchlistnews.com · tickerreport.com
Coinbase surged 11.2% on August 19, 2026, after CEO Brian Armstrong prepared to meet President Trump and Bitcoin rebounded toward $65,000. The CLARITY Act remains stuck in the Senate, leaving SEC and CFTC rulemaking as the near-term path. For crypto investors, this is a leveraged policy-plus-BTC-beta event.
Source: markets.financialcontent.com
FDA approval of Moderna's mRNA flu vaccine, with a 26.6% relative efficacy improvement over standard shots, signals a shift in seasonal flu prevention strategies for healthcare systems treating older adults.
Moderna's mRNA flu vaccine mRNA-1010 secures FDA approval, showing a 27.4% relative efficacy advantage over standard-dose in adults 65+, validating mRNA technology for seasonal influenza.
Source: livescience.com · MedPage Today
The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Source: kawc.org · wknofm.org
After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification.
Source: news.wjct.org · wdiy.org
The FDA’s imminent decision on Moderna’s mRNA flu vaccine carries high stakes for healthcare providers and the vaccine industry. While an advisory panel backed approval, political skepticism from HHS Secretary RFK Jr. and a prior agency reversal add uncertainty. The ruling could either accelerate or stall mRNA’s expansion beyond COVID-19.
A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Source: The Motley Fool · Adria Cimino
A federal judge has issued a temporary injunction against the vaccine policy agenda proposed by Robert F. Kennedy Jr., citing potential risks to public health infrastructure. While the ruling provides a reprieve for existing immunization standards, experts warn that the ongoing legal and political battle could further erode public confidence in scientific institutions.
A Massachusetts federal judge has blocked the Trump administration's attempts to dismantle the standard U.S. vaccine schedule. The ruling halts Robert F. Kennedy Jr.’s efforts to reduce recommended pediatric immunizations, citing a failure to follow established scientific and procedural laws.
Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
Source: abc11.com · abc7ny.com
Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness.
Following the latest earnings cycle, Seeking Alpha's quantitative analysis identifies a significant performance gap between biopharma innovators and retail pharmacy giants. While Incyte and UnitedHealth lead with near-perfect scores, Walgreens and Moderna have fallen into 'Strong Sell' territory.
Source: Seeking Alpha · Seeking Alpha
Wix and PAR Technology shares surged on March 4, 2026, signaling a robust appetite for e-commerce and unified commerce infrastructure. The rally, supported by broader gains in the SaaS sector including Cloudflare, highlights a shift toward high-margin digital enablement tools in the retail and restaurant landscapes.
Source: finance.yahoo.com
Moderna (MRNA) shares rose significantly on March 4, 2026, as part of a broader market rally that lifted high-growth technology and clean energy stocks. The move highlights a renewed investor appetite for innovative platforms, signaling a potential recovery for the biotech sector following a period of macro-induced volatility.
